Topic: mergers and acquisitions
Fresh off a $60 million raise, the Novo-backed startup Therachon announced plans to buy GLyPharma Therapeutic to become a multi-asset company.
Quest Diagnostics has agreed to sell off its India medical diagnostics business to Strand Life Sciences, citing a changing business model.
Hologic is acquiring Focal Therapeutics for $125 million in cash to supplement its breast-conserving surgery franchise.
Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for Syntimmune.
Medtronic moved to acquire spine surgery-focused Mazor Robotics, to merge it with its own implants, navigation and imaging offerings.
The takeover gives Amicus a ready-made pipeline of 10 gene therapies, including two that are in clinical trials.
Qiagen announced plans for global launches of tuberculosis and molecular diagnostic tests developed with two separate companies.
Allergan will fork over $195 million for Bonti, a startup founded by former Allergan executives focused on creating a new botulinum neurotoxin.
Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.
The takeover is focused on VSV candidates Boehringer sees becoming key components of its efforts to gain ground in the immuno-oncology sector.